ArticleInfectious diseases and therapy2016
Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis.
Article in Infectious diseases and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Trial
- Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data.Infectious diseases and therapy · 2025Article
- Article
- Costs and Outcomes of Clostridioides difficile Infections in Germany: A Retrospective Health Claims Data Analysis.Infectious diseases and therapy · 2025Article
- Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.BMC infectious diseases · 2024Article
- Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.BMC infectious diseases · 2024Observational
- Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation.Cardiology and therapy · 2023Article
- Epidemiology and Risk Factors of Clostridioides difficile Infections in Germany: A Health Claims Data Analysis.Infectious diseases and therapy · 2023Article
- Epidemiology of Clostridioides difficile Infections in Germany, 2010-2019: A Review from Four Public Databases.Infectious diseases and therapy · 2023Article
- Association between epidemiologic case definition categories and adverse clinical outcome in patients with Clostridiodes difficile infection in San Francisco County, California: a five-year retrospective cohort study.BMC infectious diseases · 2023Article
- Article
- Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data.Archives of gynecology and obstetrics · 2021Observational
- Opportunities for Nanomedicine inAntibiotics (Basel, Switzerland) · 2021Review
- Gastrointestinal Microbiome - What We Need to Know in Clinical Practice.GE Portuguese journal of gastroenterology · 2020Review
- Updates to Clostridium difficile Spore Germination.Journal of bacteriology · 2018Review
- [Treatment of acute and recurrent Clostridium difficile infections : What is new?]Der Internist · 2018Review
- Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.Pharmacotherapy · 2018Article
- Inhibitory Effect of Ursodeoxycholic Acid onFrontiers in microbiology · 2018Article
- Recent Progress for the Effective Prevention and Treatment of RecurrentInfectious diseases · 2018Article
- Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014.Emerging infectious diseases · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea. Recurrence rates are as high as 20-30% after standard treatment with metronidazole or vancomycin, and appear to be reduced for patients treated with fidaxomicin. According to the literature, the risk of CDI recurrence increases after the second relapse to 30-65%. Accurate data for Germany are not yet available.
methodsBased on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, treatment characteristics and course of CDI was performed. The database included high granular accounting information of about 1.46 million medically insured patients covering the period 2006-2013, being representative for Germany. The analysis was based on new-onset CDI in 2012 in patients which either received outpatient antibiotic therapy for CDI or were hospitalized.
resultsThe ICD-10 coded incidence of CDI in 2012 was 83 cases per 100,000 population. Overall mortality rates within the follow-up period of 1 year were 13.5% in inpatients with primary diagnosis of CDI, compared to 24.3% in inpatients with secondary diagnosis of CDI (P < 0.001), and 7.1% in outpatients (P < 0.001). In the median, patients with secondary diagnosis of CDI remained significantly longer hospitalized (24 vs. 9 days, P < 0.001). First recurrence of CDI was observed in 18.2% of cases with index events. There was a significantly increased risk to suffer a second and third recurrence, reaching 28.4% (P < 0.001), and 30.2% (P = 0.017), respectively. Antibiotic therapy of CDI in outpatients was performed mainly with metronidazole (in 90.8% of index events, 60.0% of first recurrences, and 43.5% of second recurrences).
conclusionThe reported incidence of CDI in Germany is higher than noted previously. The recurrence rates do increase with the number of relapses, but are lower than reported in the literature, despite dominance of metronidazole treatment in outpatients.
fundingMSD Sharp & Dohme GmbH, Haar, Germany.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.